Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations?
PARTIALLY ADDRESSED
The debate identified a critical mechanistic gap between SCFA production by gut bacteria and α-synuclein disaggregation. While SCFAs cross the blood-brain barrier, their actual concentrations in brain tissue and direct effects on protein aggregation remain unvalidated, preventing therapeutic development.
Source: Debate session sess_SDA-2026-04-01-gap-20260401-225155 (Analysis: SDA-2026-04-01-gap-20260401-225155)
Landscape Summary:
Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations? is a 0.9 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations? — INVOKE-2 (completed)